NCT04936984 is a Phase 1 clinical trial of abaloparatide-sMTS (Patheon) in Osteoporosis, sponsored by Radius Health, Inc..

Who is sponsoring NCT04936984?

NCT04936984 is sponsored by Radius Health, Inc..

What drugs are being tested in NCT04936984?

Interventions in NCT04936984: abaloparatide-sMTS (Patheon), abaloparatide-sMTS (Kindeva), abaloparatide-sMTS (Patheon), abaloparatide-sMTS (Patheon).

What condition does NCT04936984 study?

NCT04936984 studies Osteoporosis.

Is NCT04936984 still recruiting?

NCT04936984 is currently completed. Last updated 6 January 2022.

Last reviewed 2022-01-06 · How we verify

NCT04936984

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.

Completed Phase 1 Last updated 6 January 2022

What this trial tests

Phase 1 trial testing abaloparatide-sMTS (Patheon) in Osteoporosis in 36 participants. Completed in 13 August 2021.

Timeline

16 November 2020

Primary endpoint
9 February 2021

13 August 2021

Quick facts

Lead sponsor	Radius Health, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	16 November 2020
Primary completion	9 February 2021
Estimated completion	13 August 2021
Sites	1 location across United States

Drugs / interventions tested

abaloparatide-sMTS (Patheon)
abaloparatide-sMTS (Kindeva)
abaloparatide-sMTS (Patheon)
abaloparatide-sMTS (Patheon)

Conditions studied

Osteoporosis — all drugs for Osteoporosis →

Sponsor

Radius Health, Inc. — full company profile →

Who can join

Adults 40 to 65, female only, with Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study to evaluate the bioequivalence of abaloparatide between 2 abaloparatide-sMTS treatments 300 μg treatments applied to the thigh for 5 minutes.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis.
Hong P, Liu R, Rai S, Liu J, et al · · 2023 · cited 17× · PMID 36797767 · DOI 10.1186/s13018-023-03595-x
From mechanism to applications: Advanced microneedles for clinical medicine.
Yang Y, Sun H, Sun X, Wang Y, et al · · 2025 · cited 9× · PMID 40463395 · DOI 10.1016/j.bioactmat.2025.04.025
Multi-Technology Empowers Dissolving Microneedles: A Novel Strategy in Rheumatoid Arthritis.
Wei TT, Song YM, Zhai BT, Qiao JX, et al · · 2026 · PMID 41810126 · DOI 10.2147/dddt.s569186

Verify or expand the search:

Other recruiting trials for Osteoporosis

Currently open trials in the same condition.

NCT07027306 — The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fract · recruiting
NCT07367776 — Patient Education in Osteoporosis (RCT-PATOS) · NA · recruiting
NCT06731608 — OsteoPorotic fracTure preventION System (OPTIONS) Research Study · NA · recruiting
NCT07281586 — Step-down Therapy After Long-term Osteoporosis Treatment · Phase 4 · recruiting
NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting

Other Radius Health, Inc. trials

Trials by the same sponsor.

NCT04974723 — Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women · completed
NCT04663464 — Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and · Phase 1 · completed
NCT04064411 — Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis · Phase 3 · completed
NCT04366726 — Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured · Phase 1 · completed
NCT03710889 — Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04936984 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radius Health, Inc.
Last refreshed: 6 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04936984.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing